PAR

Par Drugs And Chemicals Limited

Active Pharmaceutical Ingredients manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

pardrugs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹109.53
Market cap
135 Cr
Stock P/E
9.3
P/B
1.20
Dividend yield
1.1%
ROE (FY26)
11.7%
ROCE (FY26)
15.6%
Operating margin (FY26)
13.0%
OCF / EBITDA (FY26)
95.9%
OCF / EBITDA (3Y)
88.9%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Par Drugs and Chemicals makes active pharmaceutical ingredients (the drug substances inside medicines) and fine chemicals, run from a registered office in Vadodara, Gujarat.

Company snapshot

109thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓89% of operating profit came in as cash over the last three years — profits are backed by real cash.
1 more signal from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales26 Cr24 Cr23 Cr23 Cr35 Cr21 Cr22 Cr26 Cr29 Cr29 Cr20 Cr31 Cr
Operating expenses (approx.)19 Cr19 Cr17 Cr18 Cr23 Cr20 Cr20 Cr22 Cr23 Cr23 Cr18 Cr25 Cr
EBITDA7 Cr5 Cr6 Cr4 Cr11 Cr1 Cr2 Cr4 Cr6 Cr6 Cr1 Cr6 Cr
OPM %28.4%21.8%26.7%18.7%32.9%6.7%10.9%13.7%21.2%20.7%7.4%20.4%
Other income0.05 Cr0.23 Cr-0.05 Cr0.07 Cr1 Cr0.27 Cr0.79 Cr2 Cr0.48 Cr1 Cr0.36 Cr0.94 Cr
Interest0.03 Cr0.02 Cr0.05 Cr0.02 Cr0.03 Cr0.01 Cr0.02 Cr0.02 Cr0.05 Cr0.01 Cr0.04 Cr0.02 Cr
Depreciation0.85 Cr0.87 Cr0.89 Cr0.90 Cr0.91 Cr0.91 Cr0.92 Cr0.90 Cr0.94 Cr0.93 Cr0.93 Cr0.96 Cr
Profit before tax7 Cr5 Cr5 Cr3 Cr11 Cr0.77 Cr2 Cr4 Cr6 Cr6 Cr0.83 Cr6 Cr
Tax %25.2%25.2%27.2%25.2%25.2%25.2%27.5%25.7%25.6%25.5%-2.7%25.6%
Net profit5 Cr3 Cr4 Cr3 Cr9 Cr0.58 Cr2 Cr3 Cr4 Cr5 Cr0.85 Cr5 Cr
EPS (₹)₹3.97₹2.78₹3.02₹2.06₹6.99₹0.47₹1.34₹2.70₹3.36₹3.90₹0.69₹3.83

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales49 Cr42 Cr46 Cr61 Cr75 Cr96 Cr96 Cr101 Cr104 CrSign in free for the trailing twelve months
Operating expenses (approx.)40 Cr34 Cr38 Cr45 Cr59 Cr78 Cr73 Cr81 Cr87 CrSign in free for the trailing twelve months
EBITDA8 Cr8 Cr8 Cr16 Cr16 Cr18 Cr23 Cr20 Cr17 CrSign in free for the trailing twelve months
OPM %17.4%18.8%17.7%26.4%21.7%19.0%23.9%19.3%16.5%Sign in free for the trailing twelve months
Other income0.04 Cr0.04 Cr0.09 Cr0.19 Cr0.18 Cr0.24 Cr0.24 Cr2 Cr4 CrSign in free for the trailing twelve months
Interest3 Cr2 Cr2 Cr0.64 Cr0.45 Cr0.13 Cr0.11 Cr0.08 Cr0.13 CrSign in free for the trailing twelve months
Depreciation3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr4 Cr4 CrSign in free for the trailing twelve months
Profit before tax3 Cr3 Cr3 Cr15 Cr13 Cr15 Cr20 Cr18 Cr17 CrSign in free for the trailing twelve months
Tax %42.0%41.4%26.3%21.2%27.5%24.8%25.7%25.5%24.2%Sign in free for the trailing twelve months
Net profit2 Cr1 Cr2 Cr12 Cr9 Cr11 Cr15 Cr13 Cr13 CrSign in free for the trailing twelve months
EPS (₹)——₹5.40₹18.87₹7.49₹9.21₹11.78₹10.86₹10.65Sign in free for the trailing twelve months
Dividend payout %————16.7%0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital8 Cr8 Cr4 Cr6 Cr12 Cr12 Cr12 Cr12 Cr12 Cr
Reserves11 Cr12 Cr25 Cr46 Cr48 Cr59 Cr73 Cr87 Cr100 Cr
Borrowings21 Cr18 Cr10 Cr8 Cr—————
Other liabilities16 Cr15 Cr12 Cr17 Cr19 Cr18 Cr16 Cr20 Cr17 Cr
Total liabilities56 Cr54 Cr51 Cr76 Cr79 Cr89 Cr102 Cr119 Cr129 Cr
Fixed assets (net)42 Cr39 Cr36 Cr30 Cr34 Cr38 Cr41 Cr39 Cr36 Cr
CWIP———5 Cr0.25 Cr0.25 Cr0.03 Cr0 Cr0.72 Cr
Investments0.06 Cr0.06 Cr0.06 Cr0.01 Cr0.01 Cr0.01 Cr0.01 Cr25 Cr27 Cr
Loans & advances—————0.08 Cr0.09 Cr0.10 Cr0.11 Cr
Inventories4 Cr4 Cr4 Cr3 Cr5 Cr5 Cr4 Cr6 Cr5 Cr
Trade receivables8 Cr9 Cr9 Cr12 Cr18 Cr17 Cr14 Cr17 Cr12 Cr
Cash & bank0.02 Cr0.06 Cr0.03 Cr21 Cr16 Cr22 Cr37 Cr28 Cr42 Cr
Other assets2 Cr2 Cr2 Cr5 Cr5 Cr5 Cr6 Cr5 Cr6 Cr
Total assets56 Cr54 Cr51 Cr76 Cr79 Cr89 Cr102 Cr119 Cr129 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity9 Cr4 Cr8 Cr12 Cr8 Cr13 Cr20 Cr16 Cr16 Cr
Cash from investing-2 Cr-0.60 Cr-0.25 Cr0.05 Cr-3 Cr-7 Cr-6 Cr-25 Cr-2 Cr
Cash from financing-8 Cr-4 Cr-7 Cr2 Cr-10 Cr-0.0024 Cr0 Cr0 Cr0 Cr
Net cash flow-0.91 Cr0.05 Cr-0.03 Cr14 Cr-5 Cr6 Cr14 Cr-9 Cr14 Cr
Free cash flow (OCF − Capex)7 Cr4 Cr7 Cr7 Cr4 Cr6 Cr14 Cr15 Cr14 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %14.2%12.6%13.3%25.7%22.0%21.4%22.9%18.2%15.6%
ROE %9.6%7.2%8.3%22.2%15.4%15.9%16.9%13.5%11.7%
Debtor days617567759065526042
Inventory days748381495848465646
Days payable14510793111131725910170
Cash conversion cycle-105155131640391618
OCF / EBITDA %108.4%54.1%92.5%75.5%46.8%73.5%88.7%82.9%95.9%
OCF / EBITDA % (3 years)——85.5%——65.5%72.0%82.3%88.9%
Debt / equity1.080.880.360.15—0.00—0.00—
Current ratio———2.582.933.534.793.314.68
Net debt / EBITDA2.462.271.26-0.84—-1.22-1.61-1.41-2.44